Edouard C. Nice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edouard C. Nice has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
B. Catimel
3 shared publicationsBruno Catimel
Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Parkville, Victoria, Australia
3 shared publicationsJulie Rothacker
The Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Melbourne, Australia
3 shared publicationsA.W. Burgess
2 shared publicationsAntony W. Burgess
Ludwig Institute for Cancer Research, P.O. Royal Melbourne Hospital, Parkville, Victoria 3052, Australia
2 shared publicationsJ. Rothacker
2 shared publications
Latest Publications
- 1 April 2008
- Vol. 11 (4) , 252-5
Proteomics - 13th annual symposium.
- 1 December 2007
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 4 (6) , 705-707
4th International Peptide Symposium in conjunction with the 7th Australian Peptide Symposium and the 2nd Asia–Pacific International Peptide Symposium
- 1 December 2007
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 4 (6) , 705-707
4th International Peptide Symposium in conjunction with the 7th Australian Peptide Symposium and the 2nd Asia–Pacific International Peptide Symposium
- 26 November 2007
- Published by Wiley in Electrophoresis
- Vol. 28 (23) , 4435-4446
A novel magnetic bead‐based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon cancer
Telomerase activity is elevated in more than 85% of cancer cells and absent in most of the normal cells and thus represents a potential cancer biomarker. We report its measurement in colon and bladder cancer cells captured using antibody‐coated magnetic beads. The cells are lysed and telomerase activity is detected using a biosensor assay that employs an oligonucleotide containing the telomerase recognition sequence also covalently coupled to magnetic beads. Telomerase activity is measured by the incorporation of multiple biotinylated nucleotides at the 3′‐end of the oligonucleotide strands during elongation which are then reacted with streptavidin‐conjugated horseradish peroxidase. A luminescent signal is generated when hydrogen peroxidase is added in the presence of luminol and a signal enhancer. LOD experiments confirm sensitivity down to ten cancer cell equivalents. The telomerase assay reliably identified patient samples considered by an independent pathological review to contain cancer cells. Samples from normal healthy volunteers were all telomerase negative. The assay, which is amenable to automation, demonstrated high sensitivity and specificity in a small clinical cohort, making it of potential benefit as a first line assay for detection and monitoring of colon and bladder cancer.
- 26 November 2007
- Published by Wiley in Electrophoresis
- Vol. 28 (23) , 4435-4446
A novel magnetic bead‐based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon cancer
Telomerase activity is elevated in more than 85% of cancer cells and absent in most of the normal cells and thus represents a potential cancer biomarker. We report its measurement in colon and bladder cancer cells captured using antibody‐coated magnetic beads. The cells are lysed and telomerase activity is detected using a biosensor assay that employs an oligonucleotide containing the telomerase recognition sequence also covalently coupled to magnetic beads. Telomerase activity is measured by the incorporation of multiple biotinylated nucleotides at the 3′‐end of the oligonucleotide strands during elongation which are then reacted with streptavidin‐conjugated horseradish peroxidase. A luminescent signal is generated when hydrogen peroxidase is added in the presence of luminol and a signal enhancer. LOD experiments confirm sensitivity down to ten cancer cell equivalents. The telomerase assay reliably identified patient samples considered by an independent pathological review to contain cancer cells. Samples from normal healthy volunteers were all telomerase negative. The assay, which is amenable to automation, demonstrated high sensitivity and specificity in a small clinical cohort, making it of potential benefit as a first line assay for detection and monitoring of colon and bladder cancer.
- 1 October 2007
- Published by Elsevier in Journal of Chromatography A
- Vol. 1168 (1-2) , 190-210
Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis
- 1 October 2007
- Published by Elsevier in Journal of Chromatography A
- Vol. 1168 (1-2) , 190-210
Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis
- 15 June 2006
- Published by Wiley in Biomedical Chromatography
- Vol. 20 (6-7) , 569-575
Purification and characterization of a high specificity polyclonal antibody to the adenomatous polyposis coli tumour suppressor protein
Recombinant proteins, commonly expressed in fusion with an affinity tag to facilitate purification, are often used as immunogens for polyclonal antibody production. Careful immunopurification of the antibody product is often the key to obtaining a high‐specificity polyclonal antibody against the protein domain of interest. This study describes the purification and characterization of such an antibody directed against the adenomatous polyposis coli (APC) tumour suppressor. We used a combination of affinity chromatography and biosensor analysis to optimize and monitor antibody purification. This antibody was then characterized by immunoprecipitation, proteomic analyses and immunofluorescence staining and shown to be a valuable reagent for the study of APC biology. Using this antibody we successfully isolated and identified APC, using MS/MS, from transfected cell lines. A novel phosphorylation site on APC was identified at ser 1436. Similar strategies involving multiple immuno‐affinity steps coupled with surface plasmon resonance (SPR), immunoprecipitation proteomic and immunofluorescence analyses should be generally applicable for the purification and characterization of other polyclonal antibodies. Copyright © 2006 John Wiley & Sons, Ltd.
- 15 June 2006
- Published by Wiley in Biomedical Chromatography
- Vol. 20 (6-7) , 569-575
Purification and characterization of a high specificity polyclonal antibody to the adenomatous polyposis coli tumour suppressor protein
Recombinant proteins, commonly expressed in fusion with an affinity tag to facilitate purification, are often used as immunogens for polyclonal antibody production. Careful immunopurification of the antibody product is often the key to obtaining a high‐specificity polyclonal antibody against the protein domain of interest. This study describes the purification and characterization of such an antibody directed against the adenomatous polyposis coli (APC) tumour suppressor. We used a combination of affinity chromatography and biosensor analysis to optimize and monitor antibody purification. This antibody was then characterized by immunoprecipitation, proteomic analyses and immunofluorescence staining and shown to be a valuable reagent for the study of APC biology. Using this antibody we successfully isolated and identified APC, using MS/MS, from transfected cell lines. A novel phosphorylation site on APC was identified at ser 1436. Similar strategies involving multiple immuno‐affinity steps coupled with surface plasmon resonance (SPR), immunoprecipitation proteomic and immunofluorescence analyses should be generally applicable for the purification and characterization of other polyclonal antibodies. Copyright © 2006 John Wiley & Sons, Ltd.
- 1 March 2003
- Published by Wiley in Biomedical Chromatography
- Vol. 17 (2-3) , 201-211
Strategies for the purification of laminin‐10 for studies on colon cancer metastasis
Signals from the epidermal growth factor (EGF) receptor family are thought to combine with integrin‐dependent adhesion to laminins to contribute to disease progression and metastasis in cancer. To date, little is known about the mechanisms by which these signals interact. Recently, we have shown that the colon cancer cell line LIM1215 secretes and adheres to laminin‐10 through multiple integrin receptors, and that EGF stimulates spreading and migration of these cells on the same substrate. Additionally laminin‐10/11 has been shown by immunohistochemistry to be present at the invasive edge of moderately differentiated colon cancers. To enable detailed structure–function studies to be undertaken, it is important to be able to rapidly obtain highly purified native laminin‐10 from bulk biological samples in reasonable yield. The development of a multidimensional micropurification scheme to achieve this is presented and compared with other reported methods for the purification of laminins. Copyright © 2003 John Wiley & Sons, Ltd.
- 1 March 2003
- Published by Wiley in Biomedical Chromatography
- Vol. 17 (2-3) , 201-211
Strategies for the purification of laminin‐10 for studies on colon cancer metastasis
Signals from the epidermal growth factor (EGF) receptor family are thought to combine with integrin‐dependent adhesion to laminins to contribute to disease progression and metastasis in cancer. To date, little is known about the mechanisms by which these signals interact. Recently, we have shown that the colon cancer cell line LIM1215 secretes and adheres to laminin‐10 through multiple integrin receptors, and that EGF stimulates spreading and migration of these cells on the same substrate. Additionally laminin‐10/11 has been shown by immunohistochemistry to be present at the invasive edge of moderately differentiated colon cancers. To enable detailed structure–function studies to be undertaken, it is important to be able to rapidly obtain highly purified native laminin‐10 from bulk biological samples in reasonable yield. The development of a multidimensional micropurification scheme to achieve this is presented and compared with other reported methods for the purification of laminins. Copyright © 2003 John Wiley & Sons, Ltd.
- 1 January 2002
- Published by Taylor & Francis in Growth Factors
- Vol. 20 (2) , 71-80
Rapid Microscale Enzymic Semisynthesis of Epidermal Growth Factor (EGF) Analogues
Epidermal Growth Factor (EGF) is a small growth factor containing 53 amino acid residues capable of stimulating the proliferation of both mesenchymal and epithelial cells. Comparison of the amino acid sequences of EGF from several species, and related proteins that can bind to the EGF receptor (e.g. TGFalpha, VGF, heparin-binding EGF, and betacellulin), suggests that Leu47, which is highly conserved, is important for biological function. Additionally, we have shown previously, using a combination of trypsin and carboxypeptidase Y digestion of native murine EGF, that removal of Leu47 results in more than 100-fold decrease in both receptor binding and mitogenic activity. We now describe a micromethod for the rapid generation of C-terminally modified EGFs to investigate further the role of C-terminal residues in determining functional activity. These analogues have been generated by digesting native murine EGF with trypsin, purifying the biologically inactive, but structurally intact, EGF1-45 core by micropreparative RP-HPLC, and then reversing the action of trypsin to couple synthetic peptides (e.g. DL, DI, DF, EL, DLLW) onto the C-terminus of the EGF1-45 core. This enzymic semisynthesis method allows multiple derivatives to be generated rapidly from microgram quantities of EGF1-45 in sufficient quantities for sensitive biological and physicochemical analysis. We have validated the method by regenerating EGF1-47 from EGF1-45 with equivalent mitogenic and receptor binding activity to EGF1-47 generated from wild type EGF by digestion with trypsin and carboxypeptidase Y. We have also investigated the effect of substituting alternative normal or nonphysiological amino acids (e.g. allo-Ile) for Asp46, Leu47 or Arg48. Even small changes in these C-terminal residues reduce the mitogenic potency of the analogue.
- 1 January 2002
- Published by Taylor & Francis in Growth Factors
- Vol. 20 (2) , 71-80
Rapid Microscale Enzymic Semisynthesis of Epidermal Growth Factor (EGF) Analogues
Epidermal Growth Factor (EGF) is a small growth factor containing 53 amino acid residues capable of stimulating the proliferation of both mesenchymal and epithelial cells. Comparison of the amino acid sequences of EGF from several species, and related proteins that can bind to the EGF receptor (e.g. TGFalpha, VGF, heparin-binding EGF, and betacellulin), suggests that Leu47, which is highly conserved, is important for biological function. Additionally, we have shown previously, using a combination of trypsin and carboxypeptidase Y digestion of native murine EGF, that removal of Leu47 results in more than 100-fold decrease in both receptor binding and mitogenic activity. We now describe a micromethod for the rapid generation of C-terminally modified EGFs to investigate further the role of C-terminal residues in determining functional activity. These analogues have been generated by digesting native murine EGF with trypsin, purifying the biologically inactive, but structurally intact, EGF1-45 core by micropreparative RP-HPLC, and then reversing the action of trypsin to couple synthetic peptides (e.g. DL, DI, DF, EL, DLLW) onto the C-terminus of the EGF1-45 core. This enzymic semisynthesis method allows multiple derivatives to be generated rapidly from microgram quantities of EGF1-45 in sufficient quantities for sensitive biological and physicochemical analysis. We have validated the method by regenerating EGF1-47 from EGF1-45 with equivalent mitogenic and receptor binding activity to EGF1-47 generated from wild type EGF by digestion with trypsin and carboxypeptidase Y. We have also investigated the effect of substituting alternative normal or nonphysiological amino acids (e.g. allo-Ile) for Asp46, Leu47 or Arg48. Even small changes in these C-terminal residues reduce the mitogenic potency of the analogue.
- 8 December 2001
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 58 (6) , 493-503
The use of coiled-coil interactions for the analysis and micropreparative isolation of adenomatous polyposis coli protein complexes
The coiled coil is a common structural motif found both as the dominant structure in fibrous proteins and as an oligomerization domain in a variety of cytoskeletal and extracellular matrix proteins. Coiled‐coils typically consist of two to four helices that are supercoiled around one another in either parallel or antiparallel orientations. In the past few years our knowledge of the structure and specificity of coiled coil interactions has increased, allowing the de novo design and preparation of coiled‐coils with well‐defined structure and specificity. Indeed, the design and synthesis of a peptide that binds specifically to a single coiled‐coil‐containing protein, adenomatous polyposis coli (APC) has been reported. We have optimized solid‐phase synthesis techniques to produce a modified form of the anti‐APC peptide that contains a biotin moiety specifically placed so as to allow selective orientation onto the surface of a biosensor or affinity support. These peptide surfaces have been used to both monitor and purify APC and APC complexes from cellular extracts.
- 8 December 2001
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 58 (6) , 493-503
The use of coiled-coil interactions for the analysis and micropreparative isolation of adenomatous polyposis coli protein complexes
The coiled coil is a common structural motif found both as the dominant structure in fibrous proteins and as an oligomerization domain in a variety of cytoskeletal and extracellular matrix proteins. Coiled‐coils typically consist of two to four helices that are supercoiled around one another in either parallel or antiparallel orientations. In the past few years our knowledge of the structure and specificity of coiled coil interactions has increased, allowing the de novo design and preparation of coiled‐coils with well‐defined structure and specificity. Indeed, the design and synthesis of a peptide that binds specifically to a single coiled‐coil‐containing protein, adenomatous polyposis coli (APC) has been reported. We have optimized solid‐phase synthesis techniques to produce a modified form of the anti‐APC peptide that contains a biotin moiety specifically placed so as to allow selective orientation onto the surface of a biosensor or affinity support. These peptide surfaces have been used to both monitor and purify APC and APC complexes from cellular extracts.
- 30 October 2001
- Published by Elsevier in Journal of Biochemical and Biophysical Methods
- Vol. 49 (1-3) , 289-312
The use of biosensors for microaffinity purification: an integrated approach to proteomics
- 30 October 2001
- Published by Elsevier in Journal of Biochemical and Biophysical Methods
- Vol. 49 (1-3) , 289-312
The use of biosensors for microaffinity purification: an integrated approach to proteomics
- 1 January 2001
- Published by Springer Nature in Letters in Peptide Science
- Vol. 8 (3/5) , 211-220
Use of thiazolidine-mediated ligation for site specific biotinylation of mouse EGF for biosensor immobilisation
- 1 January 2001
- Published by Springer Nature in Letters in Peptide Science
- Vol. 8 (3/5) , 211-220
Use of thiazolidine-mediated ligation for site specific biotinylation of mouse EGF for biosensor immobilisation